Ovarian microcystic stromal tumour

From Libre Pathology
Revision as of 10:26, 16 October 2019 by Michael (talk | contribs)
Jump to navigation Jump to search
Ovarian microcystic stromal tumour
Diagnosis in short

Microcystic stromal tumour of ovary. H&E stain.

LM microscopic cysts alternating with solid cellular regions, hyalinized fibrous stroma
LM DDx other sex cord stromal tumours
IHC CD10 +ve (cytoplasmic), beta-catenin (nuclear) +ve, WT-1 +ve, cyclin D1 +ve, inhibin -ve, calretinin -ve, ER-, PR-
Site ovary, testis

Prevalence rare, evolving entity
Prognosis unknown
Clin. DDx other ovarian tumours, testicular tumours
Treatment excision

Ovarian microcystic stromal tumour (abbreviated MST), also microcystic stromal tumour of the ovary, is a rare ovarian tumour.




  • Microcysts alternating with solid cellular regions.
  • Hyalinized fibrous stroma.





  • CD10 +ve (cytoplasmic).
  • Beta-catenin +ve (nuclear).
  • WT1 +ve.
  • Cyclin D1 +ve.
  • Inhibin -ve.
  • Calretinin -ve.
  • ER -ve.
  • PR -ve.


  • CTNNB1 mutation.[4]


  1. Zhu, P.; Duan, Y.; Ao, Q.; Wang, G. (Oct 2018). "Microcystic Stromal Tumor of Testicle: First Case Report and Literature Review.". Cancer Res Treat 50 (4): 1452-1457. doi:10.4143/crt.2017.414. PMID 29169232.
  2. Irving, JA.; Lee, CH.; Yip, S.; Oliva, E.; McCluggage, WG.; Young, RH. (Oct 2015). "Microcystic Stromal Tumor: A Distinctive Ovarian Sex Cord-Stromal Neoplasm Characterized by FOXL2, SF-1, WT-1, Cyclin D1, and β-catenin Nuclear Expression and CTNNB1 Mutations.". Am J Surg Pathol 39 (10): 1420-6. doi:10.1097/PAS.0000000000000482. PMID 26200099.
  3. 3.0 3.1 McCluggage, WG.; Chong, AS.; Attygalle, AD.; Clarke, BA.; Chapman, W.; Rivera, B.; Foulkes, WD. (Feb 2019). "Expanding the morphological spectrum of ovarian microcystic stromal tumour.". Histopathology 74 (3): 443-451. doi:10.1111/his.13755. PMID 30325056.
  4. Na, K.; Kim, EK.; Jang, W.; Kim, HS. (Jun 2017). "CTNNB1 Mutations in Ovarian Microcystic Stromal Tumors: Identification of a Novel Deletion Mutation and the Use of Pyrosequencing to Identify Reported Point Mutation.". Anticancer Res 37 (6): 3249-3258. doi:10.21873/anticanres.11688. PMID 28551672.